ADHD Supplement Firm Turns Attention To Ingredient Supply After NAD Review

Vaya marketed Vayarin supplement in the US, but its parent firm, specialty chemicals company Enzymotec, responds to NAD request for substantiation by saying that it changed "its strategy to focus on serving as an ingredient-supplier rather than engaging in the sale of consumer products." Change includes closing Vaya and ceasing Vayarin sales in the US.

Closed sign

More from Regulation

More from Policy & Regulation